Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858320 · ClinicalTrials.gov registry record · Phase 3
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
A Phase 3 study of Heart Failure, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 5
- Study locations
NCT05858320: Completed Phase 3 study of Heart Failure, sponsored by University of Michigan.
NCT05858320 is a Phase 3 study of Heart Failure that has completed, run by University of Michigan. The registered enrollment target is 225 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05858320, a Phase 3 study of Heart Failure, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 5
- Study locations
Study Summary
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a computable medication optimization algorithm. The algorithm provides a medication quality score and outputs medication optimization recommendations written in a patient -friendly manner.
Primary Outcome
Change in GDMT medication score generated by the computable algorithm from baseline to Week 12
Conditions Studied
Interventions
- OTHER SmartHF application
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Hospital and Health System - Detroit
- Trinity Healthcare St. Joseph Mercy Ann Arbor - Ypsilanti
Georgia
- Emory University, Grady Hospital - Atlanta
Missouri
- Washington University, Barns Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 3 |
What the finished NCT05858320 record still lists
NCT05858320 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which SmartHF application is the first listed.
NCT05858320 lists 5 locations in 3 states (Michigan, Georgia, Missouri).
Frequently Asked Questions
What is clinical trial NCT05858320 about?
NCT05858320 is a clinical study titled "The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients". The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the...
What is the current status of trial NCT05858320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2023-07-21. Estimated completion is 2025-12-01.
What conditions does trial NCT05858320 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05858320?
The interventions under investigation include: SmartHF application (OTHER).
Who is sponsoring clinical trial NCT05858320?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858320 being conducted?
This trial has 5 study locations across Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05858320's enrollment target sits among peer trials
225 155th of 397 higher than 242 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI